论文部分内容阅读
目的探讨p504s、p63和ki67在前列腺癌中的表达情况及联合检测的临床意义。方法应用免疫组织化学SP法检测70例前列腺增生和28例前列腺癌中p504s、p63和ki67的表达情况。结果前列腺癌患者p504s、p63、ki67表达阳性率均高于前列腺增生患者,差异均有显著性(P<0.01)。p504s、p63和ki67单独检测的灵敏度分别为89.3%、78.6%和67.8%,特异度分别为92.9%、88.6%和94.3%。而三者联合检测的灵敏度分别为92.8%、82.1%、75%,特异度分别为92.9%、85.7%、95.7%。结论p504s、p63、ki67可作为前列腺癌的肿瘤标记物,协助临床上前列腺癌的诊断;联合检测可提高前列腺癌的诊断准确率。
Objective To investigate the expression of p504s, p63 and ki67 in prostate cancer and their clinical significance. Methods Immunohistochemical SP method was used to detect the expression of p504s, p63 and ki67 in 70 cases of benign prostatic hyperplasia and 28 cases of prostatic cancer. Results The positive rates of p504s, p63 and ki67 in prostate cancer patients were significantly higher than those in benign prostatic hyperplasia patients (P <0.01). The sensitivity of p504s, p63 and ki67 alone were 89.3%, 78.6% and 67.8%, respectively, and the specificity was 92.9%, 88.6% and 94.3% respectively. The sensitivity of the three detection were 92.8%, 82.1%, 75%, specificity of 92.9%, 85.7%, 95.7% respectively. Conclusions p504s, p63 and ki67 can be used as tumor markers in prostate cancer to assist in the diagnosis of clinical prostate cancer. Combined detection can improve the diagnostic accuracy of prostate cancer.